BioPharma Resources

Investigational drug · Phase 3

ALKS 2680

Also called: Alixorexton

Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

7

5 still active

All registered trials

7

Any phase or sponsor naming "ALKS 2680"

First trial start

2024

Mar 24, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ALKS 2680", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Narcolepsy Type 1
  • Narcolepsy Type 2
  • Idiopathic Hypersomnia

Approved drugs for the same conditions: Narcolepsy · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "ALKS 2680" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 5 on PubMed

Also in development for Narcolepsy Type 1

  • TAK-360Phase 34 trials

    Takeda · Narcolepsy Type 1, Idiopathic Hypersomnia, Narcolepsy Type 2

  • ORX750Phase 22 trials

    Centessa Pharmaceuticals (UK) Limited · Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.